SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (995)8/14/2001 5:44:04 PM
From: Arthur Radley  Respond to of 1475
 
From a note on my calendar..it appears we should be getting an update around Sept. 20 from data to be presented at the Stockholm conference. Any degree of buying coming into BTRN should give us a nice upward movement.

I hold a few shares of ISIP and the same factors apparently are coming into play there. I guess one could get really P#####off, but then when this same group starts covering we can enjoy the turn of events...at least we can hope!



To: scaram(o)uche who wrote (995)8/23/2001 10:53:21 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 1475
 
from today's MEDI release.......

Peter Kiener is joining MedImmune after 17 years with Bristol Myers Squibb (BMS), most recently holding the title of director, immunology, inflammation, and pulmonary drug discovery.

Should be perfect.

The question is, will he like what he sees, or turn tail and run in the face of CTLA4Ig and related observations?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News